6533b855fe1ef96bd12b1509

RESEARCH PRODUCT

Treatment of hepatitis B surface antigen (HBsAg)-positive chronic hepatitis with recombinant leucocyte α-A interferon

Georg HessKarl-hermann Meyer Zum BüschenfeldeWolfram H. GerlichT. H. HütterothJanusz Slusarczyk

subject

MaleHBsAglaw.invention03 medical and health sciences0302 clinical medicinelawInterferonHumansMedicineHepatitis Chronic030304 developmental biologyHepatitis0303 health sciencesHepatitis B Surface AntigensHepatologybusiness.industryvirus diseasesHomosexualityHepatitis BHepatitis Bmedicine.diseaseRecombinant Proteinsdigestive system diseases3. Good healthDiscontinuationHBeAgInterferon Type IImmunologyRecombinant DNADrug EvaluationFemale030211 gastroenterology & hepatologybusinessInterferon type Imedicine.drug

description

A total of 32 individuals with HBsAg-positive and anti-delta-negative chronic hepatitis were treated with recombinant alpha-A interferon in phase I and phase II studies. In 5/32 patients HBsAg could be eliminated and in 19/32 individuals HBeAg became negative including all those who also eliminated HBsAg. Side-effects were tolerable in most patients and were readily reversible upon discontinuation of interferon therapy. In conclusion, treatment of HBsAg-positive chronic hepatitis with interferon seems to be a promising therapeutic approach. Future studies will have to establish the optimal dose, duration of treatment and factors predicting a favourable outcome of the treatment.

yearjournalcountryeditionlanguage
1986-01-01Journal of Hepatology
https://doi.org/10.1016/s0168-8278(86)80128-3